Immunic Inc

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Immunic Inc reports Q4 sales growth, faces challenges in psoriasis trials

Immunic Inc's financial performance in Q4 2022 was marked by strong sales and strategic financing, offset by challenges in the IMU-935 psoriasis trial. The company's focus on advancing its pipeline, exploring new treatment approaches, and upcoming milestones present opportunities for growth and innovation.

Immunic Inc reports Q1 loss, highlights clinical progress and partnership opportunities

Immunic Inc's Q1 2023 performance reflects a strong focus on advancing clinical programs despite reporting a net loss.
The company's financial stability, positive clinical data, and upcoming milestones highlight its potential for growth and innovation.
Challenges in managing expenses and gaining regulatory approvals are balanced by opportunities for partnerships and market differentiation.
Overall, Immunic Inc's strategic approach to R&D and openness to collaborations position it well for future success in the biopharmaceutical industry.

Immunic Inc reports Q2 loss, highlights promising trial results

Immunic Inc showcased solid financial positioning with sufficient cash reserves to support operations into Q4 2024, despite reporting a net loss in Q2 2023.
The positive trial results of vidofludimus calcium and IMU-856 underscore the company's strong pipeline and potential for therapeutic innovation.
While facing challenges in patient enrollment and partnership development, Immunic has opportunities to advance its clinical programs and expand its market reach.

Immunic Inc reports positive trial results and patent extension

Immunic Inc's Q3 performance reflects a focus on advancing its pipeline with positive trial results.
The company faces challenges in enrollment progress, financial sustainability, and regulatory approvals.
Opportunities lie in partnerships, upcoming milestones, and innovative treatment approaches.
Overall, Immunic Inc shows promise in its pipeline but must navigate challenges for sustained growth.

Immunic Inc reports positive clinical data and secures funding boost

Immunic Inc demonstrated strong performance in clinical trials and financial management, positioning the company for future growth and success.
With a robust pipeline, new patents, and ample funding, Immunic has the potential to drive innovation in autoimmune disease treatments.
While facing challenges in advancing drug candidates and managing expenses, Immunic can leverage opportunities for partnerships and revenue generation.
Investors should monitor Immunic's progress on upcoming milestones and the successful execution of its clinical development strategies.

Immunic Inc secures funding, patents, and positive trial data

Immunic Inc's Q1 2024 performance reflects strong financial positioning and promising clinical developments. While challenges exist in managing losses and upcoming milestones, opportunities in the gastrointestinal space and upcoming trial read-outs offer growth potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK , June 15, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in patients with relapsing-remitting multiple sclerosis (RRMS), has been published in the peer reviewed journal, Annals of Clinical and Translational Neurology. The paper, authored by coordinating investigator, Robert J.

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology

NEW YORK , June 8, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, industry and investor conferences in June: June 10-13: 13th International Congress on Autoimmunity. Evelyn Peelen, Ph.D.

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June

Immunic's (IMUX) phase II CALDOSE-1 study, evaluating vidofludimus calcium in patients with moderate-to-severe ulcerative colitis, fails to meet primary endpoint. Stock down.

Immunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails

Immunic (IMUX) stock is falling hard on Thursday after the company released poor results from a recent Phase 2 clinical trial. The post Why is Immunic (IMUX) Stock Plunging 40% Today?

Why is Immunic (IMUX) Stock Plunging 40% Today?

– Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids – – In UC Population Without Concurrent Steroid Use, Pooled Vidofludimus Calcium Data Suggest Activity in Clinical Remission Over Placebo; Counterbalanced by Interference Observed in the UC Population with Concurrent Steroid Use – – Company Does Not Plan Further Development Activities in Ulcerative Colitis Without a Partner – – Focus to Remain on Ongoing Phase 3 Development of Vidofludimus Calcium in Multiple Sclerosis, and Ongoing IMU-935 and IMU-856 Programs with Clinical Data for Both Expected in 2022 – – $93.1 Million in Cash and Cash Equivalents as of May 31, 2022 Expected to Fund Immunic Into the Fourth Quarter of 2023 – – Conference Call and Webcast, Including a Corporate Update, to be Held today, June 2, 2022 at 8:00 am ET – NEW YORK , June 2, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today reported top-line data from its phase 2 CALDOSE-1 trial of lead asset, vidofludimus calcium (IMU-838), the company's selective oral DHODH inhibitor, in patients with moderate-to-severe ulcerative colitis (UC) (clinicaltrials.gov: NCT03341962). The trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10.

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Immunic Inc. (NASDAQ:IMUX ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Daniel Vitt – Chief Executive officer, President & Director Glenn Whaley – Vice President of Finance and Principal Financial & Accounting Officer Conference Call Participants Thomas Smith – SVB Leerink Yasmeen Rahimi – Piper Sandler Andreas Argyrides – Wedbush Matthew Kaplan – Lautenbach Tallmann Boobalan Pachaiyappan – H.C. Wainwright Zegbeh Jallah – Roth Capital Operator Good morning and welcome to Immunic's First Quarter 2022 Earnings Call.

Immunic Inc. (IMUX) CEO Daniel Vitt on Q1 2022 Results - Earnings Call Transcript

– Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month – – Part C Portion of Phase 1 Trial of IMU-935 in Psoriasis Patients Ongoing; Data Expected in the Second Half of 2022 – – Current Cash and Cash Equivalents Expected to Fund Immunic Into the Third Quarter of 2023 – – Webcast to be Held Today, May 10, 2022, at 8:00 am ET – NEW YORK , May 10, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the first quarter ended March 31, 2022 and provides a corporate update. "The first quarter of 2022 was marked by continued momentum, both financially and within our clinical pipeline programs," stated Daniel Vitt, Ph.D.

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update

– First Time Patients Will be Treated with the Company's Orally Available Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium  – NEW YORK , May 5, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the start of the patient cohorts in its ongoing phase 1 clinical trial of IMU-856, the company's third clinical asset, in patients with celiac disease. IMU-856 is an orally available and systemically acting small molecule modulator that targets an undisclosed epigenetic regulator.

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease

– Webcast to be Held at 8:00 am ET on May 10, 2022 – NEW YORK, May 3, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the first quarter ended March 31, 2022, including a corporate update, on Tuesday, May 10, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update

NEW YORK , April 25, 2022 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following, upcoming investor and industry conferences: April 27-28: B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference.

Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences

NEW YORK , March 16, 2022 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that Glenn Whaley, CPA, who has served as Vice President Finance, Principal Financial and Accounting Officer since April 2020, has been promoted to the position of Chief Financial Officer. "Glenn has done an outstanding job since joining the company in 2019 and his more than 30 years of experience in accounting and finance have been invaluable to the smooth running of our U.S. operations as we have continued to progress our pipeline and pursue the many opportunities before us," commented Daniel Vitt, Ph.D.

Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer

NEW YORK, March 8, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March: March 13-15: 34th Annual Roth Conference. Duane Nash, M.D.

Immunic, Inc. to Participate in Investor and Scientific Conferences in March

Immunic Inc. (IMUX) CEO Daniel Vitt on Q4 2021 Results - Earnings Call Transcript

NEW YORK, Feb. 24, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent activity. "2021 was another year of tremendous achievement for Immunic, punctuated by significant clinical progress across our key pipeline programs, including our lead product candidate, selective oral DHODH inhibitor, vidofludimus calcium (IMU-838) and IMU-935, a highly potent and selective oral IL-17 inhibitor.

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

NEW YORK, Feb. 18, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data on the potent anti-inflammatory activity of vidofludimus calcium (IMU-838), the company's selective oral DHODH inhibitor, at the 17th Congress of European Crohn's and Colitis Organization (ECCO).

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Coliti

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the fourth quarter and year ended December 31, 2021, including a corporate update, on Thursday, February 24, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

NEW YORK, Feb. 8, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in February: February 16-18: SVB Leerink 11th Annual Global Healthcare Conference. Daniel Vitt, Ph.D.

Immunic, Inc. to Participate in Investor and Scientific Conferences in February

NEW YORK, Feb. 2, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/644581, entitled, "IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation". The company also received notice of allowance of patent application EP18762111.5 in Europe, and notice of grant of patent application 2018330633 in Australia.

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

Here is how Immunic (IMUX) and Owens & Minor (OMI) have performed compared to their sector so far this year.

Is Immunic (IMUX) Stock Outpacing Its Medical Peers This Year?

The consensus price target hints at a 357.4% upside potential for Immunic (IMUX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Immunic (IMUX) Climb 357% to Reach the Level Wall Street Analysts Expect?

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced positive unblinded safety, tolerability and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD) of its phase 1 clinical trial of IMU-935 in healthy human subjects. In addition, the company announced newly available preclinical in vivo data showing that IMU-935 maintains normal thymocyte maturation in relevant acute and chronic mouse models.

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

NEW YORK, Dec. 9, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in its open-label phase 1 trial of IMU-935, a highly potent and selective inverse agonist of the transcription factor RORγt, in metastatic castration-resistant prostate cancer (mCRPC). The trial's Principal Investigator is Johann Sebastian de Bono, M.D.

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer

NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer and President, will participate in a fireside chat at the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference, taking place November 29-December 2, 2021.

Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference

NEW YORK, Nov. 18, 2021 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the first patient enrolled in its phase 3 ENSURE program of lead asset, vidofludimus calcium (IMU-838), the company's selective oral DHODH inhibitor, in patients with relapsing multiple sclerosis (RMS). "Enrollment of the first patient in ENSURE, which comes on the heels of initiating our supportive phase 2 CALLIPER trial in patients with progressive multiple sclerosis, marks an important inflection point for Immunic as we advance our lead asset, vidofludimus calcium, into active clinical phase 3 development," stated Daniel Vitt, Ph.D.

Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis

Immunic, Inc. (IMUX) CEO Daniel Vitt on Q3 2021 Results - Earnings Call Transcript

News for Immunic Inc Stock (IMUX)